1921
Volume 78, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

To date, no immune correlates for blood stage–specific immunity against malaria parasites have been identified. Growth and/or invasion inhibition assays using sera from Phase 2a/b trials will aid in determining whether correlations with protective immunity can be established for these assays. A major constraint in the ability to evaluate functional antibody activities from populations in endemic areas is the relatively limited availability of sufficient sample quantity. For this reason, we developed a miniaturized and high-throughput method to measure growth inhibitory activity by quantification of parasite lactate dehydrogenase (pLDH) in a 384-microtiter plate format. This culture method can be extended beyond the pLDH-based readout to other techniques commonly used to determine growth/invasion inhibition.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2008.78.468
2008-03-01
2017-11-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/78/3/0780468.html?itemId=/content/journals/10.4269/ajtmh.2008.78.468&mimeType=html&fmt=ahah

References

  1. John CC, O’Donnell RA, Sumba PO, Moormann AM, Koning-Ward TFD, King CL, Kazura JW, Crabb BS, 2004. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of the merozoite surface protein-1 (MSP-119) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 173 : 666–672.
  2. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, Lanar DE, Schluchter MD, Kazura JW, 2005. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 73 : 222–228.
  3. Diallo TO, Nguer CM, Dieye A, Spiegel A, Perraut R, Garraud O, 1999. Immune responses to P. falciparum-MSP1 antigen: lack of correlation between antibody responses and the capacity of peripheral cellular immune effectors to respond to this antigen in vitro. Immunol Lett 67 : 217–221.
  4. Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC, 2007. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother 51 : 1926–1933.
  5. Persson KE, Lee CT, Marsh K, Beeson JG, 2006. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol 44 : 1665–1673.
  6. Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long CA, Angov E, Lyon JA, 2006. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg 75 : 437–442.
  7. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW, 2002. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70 : 6948–6960.
  8. Makler MT, Hinrichs DJ, 1993. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg 48 : 205–210.
  9. Duetz WA, Kuhner M, Lohser R, 2006. Microbial and cell growth in microtiter plates. Genetic Engineering & Biotechnology News 26 : 1–4.
  10. Haynes JD, Moch JK, Smoot DS, 2002. Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA. Methods Mol Med 72 : 535–554.
  11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine 2001. Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, Rockville, MD.
  12. Bland JM, Altman DG, 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i : 307–310.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2008.78.468
Loading
/content/journals/10.4269/ajtmh.2008.78.468
Loading

Data & Media loading...

  • Received : 01 Nov 2007
  • Accepted : 15 Dec 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error